Paradigm hits the road with new inflammation treatment
Paradigm Biopharmaceutical’s nonclinical and clinical data have been accepted for presentations at major international conferences.
The company will showcase its late-stage development of an injectable pentosan polysulfate sodium (PPS) for the treatment of diseases where inflammation plays a significant pathogenic role, such as osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Three medical conferences have accepted presentations on injectable pentosan polysulfate sodium (iPPS) for treating musculoskeletal disorders.
Dr. Ravi Krishnan will speak virtually at the Symposium on Glycosaminoglycans, while Paradigm’s clinical and nonclinical studies on osteoarthritis will be presented at the American College of Rheumatology Convergence Conference.
“The acceptance of abstracts, posters and oral presentations at critical conferences is significant as it is yet another form of peer review validation within arthritis and pain management, scientific and clinical communities,” Paradigm Managing Director, Mr Paul Rennie, said.
“Such validation is expected to support product adoption amongst prescribing physicians, once on the market.”
$0.145
PARA BIO FPO [PAR]